Adele Sparavigna
Research Subjects
Adele Sparavigna has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Gilberto Bellia
IBSA Farmaceutici Italia, 26900 Lodi, Italy
4 shared publications - Andrea Maria Giori
IBSA Farmaceutici Italia, 26900 Lodi, Italy
3 shared publications Beatrice Tenconi
DermIng srl, Clinical Research and Bioengineering Institute, Monza, MB, Italy
3 shared publications- Beatrice Tenconi
DERMING Srl., Milan, Italy
3 shared publications Gilberto Bellia
IBSA Farmaceutici Italia, Lodi, Italy
3 shared publications- Laura La Penna
DERMING Srl., Milan, Italy
3 shared publications
Latest Publications
- Open Access
- 4 October 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 51 (2) , 152-156
Dual-Plane Treatment With Highly Concentrated Hybrid Cooperative Complexes of Hyaluronans for Facial Atrophic Acne Scars
BACKGROUND: Managing patients with acne scars remains an important challenge, as scarring negatively affects psychosocial wellbeing. Hyaluronic acid (HA) cross-linked fillers have demonstrated good efficacy and tolerability for the correction of acne scars but are limited by their reduced biological activity and low concentrations. OBJECTIVE: This study investigated the efficacy and safety on scars of a high-concentration (4.5%) HA-based filler with hybrid cooperative complexes (HCC) of high-molecular-weight and low-molecular-weight HA. METHODS: Participants received treatment twice; the first was provided at baseline (T0) and the second after 4 weeks (T1). Data were collected at T1 and after 4 months (T2) by photographs and instrumental evaluation of the skin. RESULTS: The study population included 28 patients. Improvements in the mean Goodman and Baron grade were significant across time points T0 and T1 (12% improvement; p = .0002) and T0 and T2 (31% improvement; p < .0001). Instrumental evaluation of the skin surface demonstrated a 20% reduction in the average deepness of acne scars after 4 months (p < .0001). No serious adverse events were reported during the study procedure. CONCLUSION: Highly concentrated (4.5%) HCC appears to be an effective option for the correction of facial acne scars.
- 4 October 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 51 (2) , 152-156
Open AccessDual-Plane Treatment With Highly Concentrated Hybrid Cooperative Complexes of Hyaluronans for Facial Atrophic Acne Scars
BACKGROUND: Managing patients with acne scars remains an important challenge, as scarring negatively affects psychosocial wellbeing. Hyaluronic acid (HA) cross-linked fillers have demonstrated good efficacy and tolerability for the correction of acne scars but are limited by their reduced biological activity and low concentrations. OBJECTIVE: This study investigated the efficacy and safety on scars of a high-concentration (4.5%) HA-based filler with hybrid cooperative complexes (HCC) of high-molecular-weight and low-molecular-weight HA. METHODS: Participants received treatment twice; the first was provided at baseline (T0) and the second after 4 weeks (T1). Data were collected at T1 and after 4 months (T2) by photographs and instrumental evaluation of the skin. RESULTS: The study population included 28 patients. Improvements in the mean Goodman and Baron grade were significant across time points T0 and T1 (12% improvement; p = .0002) and T0 and T2 (31% improvement; p < .0001). Instrumental evaluation of the skin surface demonstrated a 20% reduction in the average deepness of acne scars after 4 months (p < .0001). No serious adverse events were reported during the study procedure. CONCLUSION: Highly concentrated (4.5%) HCC appears to be an effective option for the correction of facial acne scars.
- Open Access
- 21 January 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (1) , e1743
Efficacy and tolerability of Profhilo® Structura intended to restore lateral cheek fat compartment: An observational pilot study
Background and Aims: Hyaluronic acid (HA)‐based injections are used worldwide to improve skin defects associated with aging and ultraviolet light/environmental exposure. HA formulations developed according to molecular weight or with additional components, for example, cross‐linking reagents, are limited by their low biological activity and concentration limit. NAHYCO™ technology has enabled the production of hybrid cooperative complexes (HCCs) of low and high molecular weight HA. Developed for injection into the fat compartments of the face and previously demonstrating potential benefits for adipose tissue restoration, Profhilo Structura® is a new 2 mL HCC formulation comprising low molecular weight HA (45 mg/mL) and high molecular weight HA (45 mg/mL). To evaluate the efficacy and tolerability of Profhilo Structura® to restore adipose tissue compartments in the lateral cheek fat compartment.Methods: Fifty healthy enrolled subjects received two injections, 1 month apart, and were evaluated 3 months posttreatment. Investigators performed clinical evaluations (Facial Volume Loss Scale [FVLS] and Wrinkle Severity Rating Scale [WSRS]) at different time points. Subjects also completed self‐evaluation assessments following treatment.Results: A significant improvement in FVLS and WSRS clinical scores after the first treatment was observed; treatment benefit was maintained 3 months after treatment completion and confirmed by subject self‐assessment. Most participants reported an improvement, particularly a marked reduction of wrinkles and increased skin firmness. No serious adverse events were reported, confirming the excellent safety profile of HCC injectable devices.Conclusions: Overall, the study highlighted the efficacy and tolerability of the studied medical device proving its effect on adipose tissue.
- 21 January 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (1) , e1743
Open AccessEfficacy and tolerability of Profhilo® Structura intended to restore lateral cheek fat compartment: An observational pilot study
Background and Aims: Hyaluronic acid (HA)‐based injections are used worldwide to improve skin defects associated with aging and ultraviolet light/environmental exposure. HA formulations developed according to molecular weight or with additional components, for example, cross‐linking reagents, are limited by their low biological activity and concentration limit. NAHYCO™ technology has enabled the production of hybrid cooperative complexes (HCCs) of low and high molecular weight HA. Developed for injection into the fat compartments of the face and previously demonstrating potential benefits for adipose tissue restoration, Profhilo Structura® is a new 2 mL HCC formulation comprising low molecular weight HA (45 mg/mL) and high molecular weight HA (45 mg/mL). To evaluate the efficacy and tolerability of Profhilo Structura® to restore adipose tissue compartments in the lateral cheek fat compartment.Methods: Fifty healthy enrolled subjects received two injections, 1 month apart, and were evaluated 3 months posttreatment. Investigators performed clinical evaluations (Facial Volume Loss Scale [FVLS] and Wrinkle Severity Rating Scale [WSRS]) at different time points. Subjects also completed self‐evaluation assessments following treatment.Results: A significant improvement in FVLS and WSRS clinical scores after the first treatment was observed; treatment benefit was maintained 3 months after treatment completion and confirmed by subject self‐assessment. Most participants reported an improvement, particularly a marked reduction of wrinkles and increased skin firmness. No serious adverse events were reported, confirming the excellent safety profile of HCC injectable devices.Conclusions: Overall, the study highlighted the efficacy and tolerability of the studied medical device proving its effect on adipose tissue.
- 1 November 2023
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 182 (10) , 628-633
Neck and face rejuvenation outcomes with Profhilo®: a comparative analysis between Chinese and Caucasian cohorts
Article: Neck and face rejuvenation outcomes with Profhilo®: a comparative analysis between Chinese and Caucasian cohorts - Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2023 October;182(10):628-33 - Minerva Medica - Journals
- 1 November 2023
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 182 (10) , 628-633
Neck and face rejuvenation outcomes with Profhilo®: a comparative analysis between Chinese and Caucasian cohorts
Article: Neck and face rejuvenation outcomes with Profhilo®: a comparative analysis between Chinese and Caucasian cohorts - Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2023 October;182(10):628-33 - Minerva Medica - Journals
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 1855-1856
The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside [Corrigendum]
Corrigendum for the article The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
- 1 July 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 1855-1856
Open AccessThe Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside [Corrigendum]
Corrigendum for the article The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
- Open Access
- 14 December 2022
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 15, 2693-2703
The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
A substantial reduction in the amount and quality of collagen leads to age-related deterioration of the elasticity and firmness of the skin. In recent years, multiple compounds have been developed aimed at reversing the molecular features of dermal aging. One such target for aging reversal is collagen degradation or turnover. SA1-III is a decapeptide (Ac-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln-Lys-NH2), also known as KP1, formally derived from the C-terminal portion of serpin A1, an agent known as a physiological inhibitor of neutrophil elastase, and has been the subject of laboratory and clinical studies determining its effects on modulation of collagen turnover as well as the treatment of age-associated changes of the face. This review aims to provide a bio-inspired approach focusing on the latest scientific studies that describe the compound, as well as a comprehensive appraisal of laboratory and clinical tests on skincare formulations enriched with sA1-III.
- 14 December 2022
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 15, 2693-2703
Open AccessThe Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
A substantial reduction in the amount and quality of collagen leads to age-related deterioration of the elasticity and firmness of the skin. In recent years, multiple compounds have been developed aimed at reversing the molecular features of dermal aging. One such target for aging reversal is collagen degradation or turnover. SA1-III is a decapeptide (Ac-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln-Lys-NH2), also known as KP1, formally derived from the C-terminal portion of serpin A1, an agent known as a physiological inhibitor of neutrophil elastase, and has been the subject of laboratory and clinical studies determining its effects on modulation of collagen turnover as well as the treatment of age-associated changes of the face. This review aims to provide a bio-inspired approach focusing on the latest scientific studies that describe the compound, as well as a comprehensive appraisal of laboratory and clinical tests on skincare formulations enriched with sA1-III.
- Open Access
- 14 December 2022
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 15, 2705-2719
The Role of a Novel Generation of Emollients, ‘Emollients Plus’, in Atopic Dermatitis
Emollients are the mainstay maintenance treatment for atopic dermatitis (AD). A novel generation of emollients, ‘emollients plus’, containing active, non-medicated substances, has softened the distinction between emollients and topical drugs. A literature search for selected key words was performed using PubMed. Additional papers were identified based on author expertise. Whilst the inclusion of five components of an ideal emollient has been proposed, no such consensus exists for emollients plus and they can vary markedly in their composition and modes of action for AD treatment. This could have a profound effect on their clinical efficacy. The efficacy of emollients plus in restoring and maintaining skin barrier function has been demonstrated on multiple levels, with evidence reported for their effects on the physical and biochemical, microbial, immunological, and neurosensory barriers. When selecting an appropriate AD treatment approach, the safety profiles of the available topical therapies must be carefully considered. There are several proposed treatment approaches for AD, including preventive, proactive, intermittent, and synergistic approaches. Emollients plus may be effective not only as maintenance therapy for AD, but also when used synergistically with anti-inflammatory pharmacological therapies.
- 14 December 2022
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 15, 2705-2719
Open AccessThe Role of a Novel Generation of Emollients, ‘Emollients Plus’, in Atopic Dermatitis
Emollients are the mainstay maintenance treatment for atopic dermatitis (AD). A novel generation of emollients, ‘emollients plus’, containing active, non-medicated substances, has softened the distinction between emollients and topical drugs. A literature search for selected key words was performed using PubMed. Additional papers were identified based on author expertise. Whilst the inclusion of five components of an ideal emollient has been proposed, no such consensus exists for emollients plus and they can vary markedly in their composition and modes of action for AD treatment. This could have a profound effect on their clinical efficacy. The efficacy of emollients plus in restoring and maintaining skin barrier function has been demonstrated on multiple levels, with evidence reported for their effects on the physical and biochemical, microbial, immunological, and neurosensory barriers. When selecting an appropriate AD treatment approach, the safety profiles of the available topical therapies must be carefully considered. There are several proposed treatment approaches for AD, including preventive, proactive, intermittent, and synergistic approaches. Emollients plus may be effective not only as maintenance therapy for AD, but also when used synergistically with anti-inflammatory pharmacological therapies.
- Open Access
- 17 September 2022
- Published by Wiley in The Scientific World Journal
- Vol. 2022, 1-8
Efficacy and Tolerability of Hybrid Complexes of High- and Low-Molecular-Weight Hyaluronan Intradermal Injections for the Treatment of Skin Roughness and Laxity of the Neck
This study aimed to evaluate the efficacy of a well-characterized formulation of hyaluronic acid (HA), Profhilo®, in the treatment of roughness and laxity of the neck skin. The study was performed on 25 subjects ranging in age from 40 to 65 years. Two injections of the studied product at 30-day intervals were performed, with evaluations conducted 1 and 4 months after the first injection. The efficacy was determined by clinical and multilevel instrumental evaluations. In addition, at the end of the study, the subjects completed a questionnaire related to the efficacy and tolerability of the product. The studied product was shown to induce a clear and statistically significant improvement in the skin of the neck in all the subjects, with concordant results between the clinical, instrumental, and subjects’ evaluations. The positive effects, present after the first injection, were further increased in the second and last evaluation. Notably, the product was reported to have a very high tolerability by both clinicians and subjects. In conclusion, two injections of the studied product safely induced skin amelioration in subjects with mild to moderate neck skin roughness and laxity.
- 17 September 2022
- Published by Wiley in The Scientific World Journal
- Vol. 2022, 1-8
Open AccessEfficacy and Tolerability of Hybrid Complexes of High- and Low-Molecular-Weight Hyaluronan Intradermal Injections for the Treatment of Skin Roughness and Laxity of the Neck
This study aimed to evaluate the efficacy of a well-characterized formulation of hyaluronic acid (HA), Profhilo®, in the treatment of roughness and laxity of the neck skin. The study was performed on 25 subjects ranging in age from 40 to 65 years. Two injections of the studied product at 30-day intervals were performed, with evaluations conducted 1 and 4 months after the first injection. The efficacy was determined by clinical and multilevel instrumental evaluations. In addition, at the end of the study, the subjects completed a questionnaire related to the efficacy and tolerability of the product. The studied product was shown to induce a clear and statistically significant improvement in the skin of the neck in all the subjects, with concordant results between the clinical, instrumental, and subjects’ evaluations. The positive effects, present after the first injection, were further increased in the second and last evaluation. Notably, the product was reported to have a very high tolerability by both clinicians and subjects. In conclusion, two injections of the studied product safely induced skin amelioration in subjects with mild to moderate neck skin roughness and laxity.
- 1 July 2022
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 181 (7-8) , 487-495
Hybrid cooperative complexes of high and low molecular weight hyaluronans (96 mg/3 mL) for the treatment of skin laxity of the inner arm and abdomen
BACKGROUND: The study was designed to evaluate the efficacy and safety of Profhilo (R) Body, a HA-based medical device, for the treatment of inner arm and abdomen laxity. The study has been performed in a single center, in healthy woman volunteers presenting a mild to moderate arm and abdomen laxity. The treatment consisted in two injection ses-sions, one month apart. 3mL of the studied medical device were administered for each brachial zone and 3mL for the abdomen.METHODS: The efficacy was assessed by clinical and multilevel instrumental evaluations, over three visits: at the first injection (T0); at the second injection (after one month: T1) and 4 months after the first injection. At the end of the study, the volunteers were asked to fill a questionnaire for their self-evaluation of efficacy and tolerability.RESULTS: The results highlighted the efficacy, both at clinical and instrumental levels of the applications, with aesthetic results already detectable after the first injection and maintained at the subsequent and last visit. The ameliorations de-tected by the investigators and instrumentations were confirmed by subjects' self-evaluation. Importantly, all these posi-tive effects were obtained with good to excellent tolerability as judged by both investigators and subjects. CONCLUSIONS: The present study shows that the treatment with the studied medical device was safe and efficacious for the treatment of mild to moderate inner arm and abdomen skin roughness and laxity.
- 1 July 2022
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 181 (7-8) , 487-495
Hybrid cooperative complexes of high and low molecular weight hyaluronans (96 mg/3 mL) for the treatment of skin laxity of the inner arm and abdomen
BACKGROUND: The study was designed to evaluate the efficacy and safety of Profhilo (R) Body, a HA-based medical device, for the treatment of inner arm and abdomen laxity. The study has been performed in a single center, in healthy woman volunteers presenting a mild to moderate arm and abdomen laxity. The treatment consisted in two injection ses-sions, one month apart. 3mL of the studied medical device were administered for each brachial zone and 3mL for the abdomen.METHODS: The efficacy was assessed by clinical and multilevel instrumental evaluations, over three visits: at the first injection (T0); at the second injection (after one month: T1) and 4 months after the first injection. At the end of the study, the volunteers were asked to fill a questionnaire for their self-evaluation of efficacy and tolerability.RESULTS: The results highlighted the efficacy, both at clinical and instrumental levels of the applications, with aesthetic results already detectable after the first injection and maintained at the subsequent and last visit. The ameliorations de-tected by the investigators and instrumentations were confirmed by subjects' self-evaluation. Importantly, all these posi-tive effects were obtained with good to excellent tolerability as judged by both investigators and subjects. CONCLUSIONS: The present study shows that the treatment with the studied medical device was safe and efficacious for the treatment of mild to moderate inner arm and abdomen skin roughness and laxity.
- Open Access
- 1 May 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 501-512
In vitro and in vivo Evaluation on the Safety and Efficacy of a Brand-New Intracutaneous Filler with α1-R-Collagen
Nowadays, the most advanced skin anti-aging treatments are addressed to restore the extracellular matrix (ECM) homeostasis. ECM is considered the main player not only as physical support of the tegument but also at the biochemical level, thanks to its capacity to exchange nutrients, water, cellular mediators, and growth factors within and between cells. This study aimed to evaluate the in vitro and in vivo efficacy and aesthetic performance of a brand-new intracutaneous filler. The latter is based on novel concepts: besides filling it exerts a homeostatic balance of nutrients able to delay the skin aging process by sustaining physiological rejuvenation of the tissue and in the surrounding injection/implantation area. The brand-new intracutaneous filler was tested for in vitro capacity to stimulate extracellular matrix components production. Therefore, a single session for injection of the product under study was performed by a specialized dermatologist, using the bolus technique on the zygomatic protuberance of 20 healthy female subjects with midface volume loss, caused by aging. Results confirmed the important and long-term volumizing, anti-wrinkle, the hydrating activity of this product after one single injection session. The biological outcomes also support product effectiveness in skin structure restoration.
- 1 May 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 501-512
Open AccessIn vitro and in vivo Evaluation on the Safety and Efficacy of a Brand-New Intracutaneous Filler with α1-R-Collagen
Nowadays, the most advanced skin anti-aging treatments are addressed to restore the extracellular matrix (ECM) homeostasis. ECM is considered the main player not only as physical support of the tegument but also at the biochemical level, thanks to its capacity to exchange nutrients, water, cellular mediators, and growth factors within and between cells. This study aimed to evaluate the in vitro and in vivo efficacy and aesthetic performance of a brand-new intracutaneous filler. The latter is based on novel concepts: besides filling it exerts a homeostatic balance of nutrients able to delay the skin aging process by sustaining physiological rejuvenation of the tissue and in the surrounding injection/implantation area. The brand-new intracutaneous filler was tested for in vitro capacity to stimulate extracellular matrix components production. Therefore, a single session for injection of the product under study was performed by a specialized dermatologist, using the bolus technique on the zygomatic protuberance of 20 healthy female subjects with midface volume loss, caused by aging. Results confirmed the important and long-term volumizing, anti-wrinkle, the hydrating activity of this product after one single injection session. The biological outcomes also support product effectiveness in skin structure restoration.
- Open Access
- 1 September 2020
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 13, 683-690
Evaluation of the Volumizing Performance of a New Volumizer Filler in Volunteers with Age-Related Midfacial Volume Defects
Purpose: The primary aim of this study was to evaluate the performance of the study product, in terms of volumizing activity as well as the duration of the effect, in women with age-related midfacial volume defects. In addition, the study allowed the evaluation of the tolerability of the product by both volunteers and investigators. Patients and Methods: Twenty-two female volunteers, aged 42– 60 years, participated in this study, which was performed under dermatological control in a single center. After an initial visit at baseline to verify adherence to the protocol criteria, volunteers received an injection of Aliaxin® SV (IBSA Farmaceutici Italia Srl), followed 3– 4 weeks later by a second touch-up treatment to treat eventual asymmetries. Four subsequent visits, the last performed 9 months from the first injection, were performed to evaluate clinically and instrumentally the efficacy of the treatment. Results: Clinical and statistically significant improvement in cheek volume was recorded after the first postinjection visit, and the effect was maintained until the end of the study period. A clinically measurable amelioration of wrinkle severity was also observed. By 3D picture recording and subsequent quantitative analysis, it was possible to determine the efficacy in terms of increased facial volume, which was already appreciable at the first visit, was further increased at the second and third visits and was maintained at the fourth and last visits. The injections were very well tolerated by the volunteers, as determined by their self-evaluation questionnaires. Conclusion: The results of the study confirm the esthetic performance of the study product on age-related midfacial volume defects. The very strong high-volumizing activity of the study product was not only properly determined by the investigators but also confirmed by self-evaluation by the volunteers. These effects were obtained with no appreciable undesired effects.
- 1 September 2020
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 13, 683-690
Open AccessEvaluation of the Volumizing Performance of a New Volumizer Filler in Volunteers with Age-Related Midfacial Volume Defects
Purpose: The primary aim of this study was to evaluate the performance of the study product, in terms of volumizing activity as well as the duration of the effect, in women with age-related midfacial volume defects. In addition, the study allowed the evaluation of the tolerability of the product by both volunteers and investigators. Patients and Methods: Twenty-two female volunteers, aged 42– 60 years, participated in this study, which was performed under dermatological control in a single center. After an initial visit at baseline to verify adherence to the protocol criteria, volunteers received an injection of Aliaxin® SV (IBSA Farmaceutici Italia Srl), followed 3– 4 weeks later by a second touch-up treatment to treat eventual asymmetries. Four subsequent visits, the last performed 9 months from the first injection, were performed to evaluate clinically and instrumentally the efficacy of the treatment. Results: Clinical and statistically significant improvement in cheek volume was recorded after the first postinjection visit, and the effect was maintained until the end of the study period. A clinically measurable amelioration of wrinkle severity was also observed. By 3D picture recording and subsequent quantitative analysis, it was possible to determine the efficacy in terms of increased facial volume, which was already appreciable at the first visit, was further increased at the second and third visits and was maintained at the fourth and last visits. The injections were very well tolerated by the volunteers, as determined by their self-evaluation questionnaires. Conclusion: The results of the study confirm the esthetic performance of the study product on age-related midfacial volume defects. The very strong high-volumizing activity of the study product was not only properly determined by the investigators but also confirmed by self-evaluation by the volunteers. These effects were obtained with no appreciable undesired effects.